Unió Europea -
búlgar -
EMA (European Medicines Agency)
gavreto
roche registration gmbh - pralsetinib - Карцином, недребноклетъчен белодроб - Антинеопластични средства - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
Bulgària -
búlgar -
Изпълнителна агенция по лекарствата
setinin 100 mg film - coated tablets
actavis group ptc ehf. - Кветиапин - 100 mg film - coated tablets
Bulgària -
búlgar -
Изпълнителна агенция по лекарствата
setinin 200 mg film - coated tablets
actavis group ptc ehf. - Кветиапин - 200 mg film - coated tablets
Bulgària -
búlgar -
Изпълнителна агенция по лекарствата
setinin 150 mg film - coated tablets
150 mg film - coated tablets
Bulgària -
búlgar -
Изпълнителна агенция по лекарствата
setinin 25 mg film - coated tablets
25 mg film - coated tablets
Bulgària -
búlgar -
Изпълнителна агенция по лекарствата
setinin 300 mg film - coated tablets
300 mg film - coated tablets
Bulgària -
búlgar -
Изпълнителна агенция по лекарствата
secondelle 1500 micrograms tablet
laboratorios leon farma sa - Левоноргестрел - 1500 micrograms tablet
Unió Europea -
búlgar -
EMA (European Medicines Agency)
deltyba
otsuka novel products gmbh - Деламанид - Туберкулоза, мултирезистентни - Антимикобактериални - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 и 5. Трябва да се вземат предвид официалните препоръки за правилното използване на антибактериални агенти.
Unió Europea -
búlgar -
EMA (European Medicines Agency)
lacosamide adroiq
extrovis eu ltd. - лакозамид - епилепсия - Противоэпилептические средства, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.